Table 3

Responses of SCLC xenografts to CDDP, VP16, and IFO given to tumor-bearing mice as single agents

Tumor xenograftDrugaGrowth delay in control mice (days)bGrowth delay in treated mice (days)bGrowth delay indexc% of optimal growth inhibitiond (observed at day)No. of complete regressions/ groupDuration of complete regressions in dayse
SCLC-61CDDP715275 (11)0 /5None
VP1611322.9100 (12)3 /54
IFO11363.3100 (14)7 /716
SCLC-100CDDP10.5121.132 (14)0 /8None
VP1610.5181.769 (10)0 /8None
IFO9.519.52.190 (13)1 /62
SCLC-6CDDP8101.376 (5)2 /52
VP167111.648 (8)0 /7None
IFO714279 (10)0 /7None
SCLC-41CDDP14241.792 (10)1 /610
VP1614110.846 (12)0 /7None
IFO1427295 (18)3 /74
SCLC-74CDDP14110.800 /8None
VP161414149 (12)0 /8None
IFO10.590.929 (3)0 /7None
SCLC-101CDDP13201.565 (13)0 /5None
VP1615171.150 (21)0 /6None
IFO13292.280 (10)0 /5None
  • a VP16 was given at 12 mg/kg/day, days 1, 2, and 3; CDDP, 6 mg/kg, day 1; IFO, 90 mg/kg/day, days 1, 2, and 3.

  • b Growth delays were calculated as the time in days required for individual tumor to reach a 5-fold increase in volume and are expressed as median values.

  • c Index of growth delay calculated as the ratio between the median growth delay in treated mice and in control mice.

  • d Expressed as the median values; in parentheses, the day of observation of optimal growth inhibition.

  • e Expressed as the median values; none indicates that no complete regression was obtained.